US Junk Bonds See Sharp Selloff as Omicron Variant Has Investors Worried




  • In Business
  • 2021-12-01 18:26:43Z
  • By GOBankingRates
tupungato / Getty Images/iStockphoto
tupungato / Getty Images/iStockphoto  

U.S. junk bonds took a dive in November as Omicron variant fears escalated concerns that lower-rated companies will struggle to pay off their debts.

See: How To Buy Bonds: A Beginner's Guide To Investing
Find: 9 Safe Investments With the Highest Returns

The decline represents the largest drop-off in junk bonds in more than a year - a high-yield bond index compiled by Ice Data Services dropped just over 1% in November. This marks only the second month in all of 2021 where the gauge has posted a negative total return - its worst showing since September of last year, per the Financial Times. The decline was driven by a slide in the price of the associated debt. The decline in the price of the debt in turn offset interest payments which the bonds provide.

The Financial Times reports that the decline is "one of the clearest indications yet of how the emergence of a new strain of coronavirus has prompted global investors to shift away from stocks and bonds of companies that are considered to be most vulnerable to the potential hit to the global economy caused by the new variant."

The downturn came mostly last Friday, Nov. 26, along with a general downturn in the S&P, both of which coincided with the onset of Omicron variant news. Governments have been forced to reimpose restrictions, lockdowns, and travel restrictions in light of the variant, with the leisure sector taking the most damage in the debt market on Nov. 26.

Bonds of triple-C and lower-rated companies returned -1.4% at that time, suggesting that investors are officially pricing in the potential end of the bull market that has dominated for the better part of the last decade.

Lower-rated companies are issued "junk" status bonds as they are the riskiest asset class. Also called "high-yield" bonds, junk bonds are typically high-risk, high-reward - or no reward at all, being perceived as a bit of a gamble from an investment point of view.

See: Stocks vs. Bonds: How To Choose the Best Investments
Find: Omicron Variant Sees Moderna, Pfizer Stocks Skyrocket as Companies Target 100-Day Vaccine Timeline

Investors are apparently now deciding it's better to bow out rather than ride the wave - at least concerning certain junk bonds - and the selloff last Friday supports the anticipation of a downturn, along with apparent dumping of debt.

  • Social Security 2022: How the COLA Will Increase Benefits for the Average Senior Couple

  • 10 Reasons You Should Claim Social Security Early

  • Save on Holiday Decor With This Instant Shopping Hack

  • How To Refinance a Mortgage

This article originally appeared on GOBankingRates.com: US Junk Bonds See Sharp Selloff as Omicron Variant Has Investors Worried

COMMENTS

More Related News

COVID Infection More Protective Than Vaccines Amid CA Delta Surge
COVID Infection More Protective Than Vaccines Amid CA Delta Surge

Those who were previously sick with COVID-19 had more protection from delta than the vaccinated, California health officials said.

'Completely full' ICUs as omicron wave stresses hospitals; FDA expands use of remdesivir. Latest COVID-19 updates

In Alabama, cases have soared and ICUs are full. Most of Vermont's hospitals face critical staffing levels, a study found. COVID-19 updates.

Striking new data shows vaccines have protected New Yorkers very well against Omicron so far
Striking new data shows vaccines have protected New Yorkers very well against Omicron so far

Data for the weeks ending January 1 and 8 showed that when infections spiked citywide, vaccinated New Yorkers were less likely to get COVID-19.

GSK, Vir ramping up U.S. output of COVID antibody drug
GSK, Vir ramping up U.S. output of COVID antibody drug
  • US
  • 2022-01-21 17:19:09Z

The U.S. government last week signed a deal with the drugmakers to buy 600,000 more doses of the therapy, sotrovimab, for an undisclosed sum. The GSK-Vir...

One chart shows how well vaccines and boosters protect against severe Omicron compared to Delta
One chart shows how well vaccines and boosters protect against severe Omicron compared to Delta

Booster shots appear to be at least 90% effective against hospitalization for both Delta and Omicron, new CDC data show.

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: Business